A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Confirm the Efficacy and Safety of a Single, Oral Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Bacterial Vaginosis

J.R. Schwebke1, F.G. Morgan2, W. Koltun3, H.S. Pentikis4,5, N. Adetoro4, C.J. Braun4,5

University of Alabama at Birmingham, Birmingham, AL1, Tidewater Clinical Research, Inc., Virginia Beach VA2, Medical Center for Clinical Research, San Diego, CA3, Symbiomix Therapeutics, LLC, Baltimore, MD4, SAJE Consulting LLC, Baltimore, MD5

Objectives: SYM-1219, a granule formulation of secnidazole, is being developed as a single oral dose therapy for bacterial vaginosis (BV). A previous study of SYM-1219 for the treatment of BV demonstrated efficacy of 1 g and 2 g of secnidazole compared to placebo, with exceptional safety and tolerability. The objective of this study was to confirm the efficacy and safety of SYM-1219 granules containing 2 g of secnidazole compared to placebo for the treatment of BV.

Methods: 189 women who met the 4 Amsel criteria for BV (discharge characteristic of BV, pH ≥4.7, ≥20% clue cells, positive whiff test) were randomized 2:1 at 22 US sites and received single oral doses of 2g of secnidazole as SYM-1219 granules or placebo. The randomization was stratified by number of reported prior episodes of BV (<3 versus ≥4 episodes within 12 months) and by race (Black versus others). Nugent score ≥4 was required for inclusion in the efficacy analyses. Patients were evaluated for efficacy between days 7-14 (interim visit) and between days 21-30 (EOS). The primary endpoint was clinical response (CR) at EOS defined as a normal vaginal discharge, negative whiff test, and clue cells <20%. Microbiological cure was a Nugent score of <4. The modified Intention-to-Treat (mITT) population was used for the efficacy analyses. Statistical comparisons used a stratified Cochran-Mantel-Haenszel (CMH) test performed at a 0.05 level of significance (2-sided).

Results: The mITT population included 164 women. Median age was 30 years. 23% reported ≥4 BV episodes in the previous year; 54% self-identified as Black. CR for SYM-1219 was superior to placebo at EOS (53% vs. 19%, p<0.001) and at the interim visit (58% vs. 25%, p<0.001). Microbiological cure for SYM-1219 was superior to placebo at EOS (44% vs. 5.3%, p<0.001) and at the interim visit (46% vs. 3.5%, p<0.001). Similar efficacy results were observed for the analyses by BV and race strata. The overall rate of AEs was low including minimal systemic AEs. Those reported above 4% (vs placebo) were as follows: vulvovaginal mycotic infection (7.2% vs 3.1%), vulvovaginal candidiasis (6.4% vs 1.6%), nausea (4.8% vs 1.6%), diarrhea (4.0% vs 1.6%), and headache (4.8% vs 3.1%).

Conclusions: These data confirm the efficacy and safety of SYM-1219 for the treatment of BV. As a single-dose, well tolerated, oral therapy, SYM-1219 could improve adherence and be an important new option for the treatment of BV.

Character and space count: 2447 (maximum allowed is 2500)

Learning Objective: At the end of this presentation, participants will be able to describe the efficacy and safety of SYM-1219 for the treatment of bacterial vaginosis.